6:07 PM
Oct 22, 2012
 |  BC Extra  |  Company News

FDA approves Supernus' epilepsy drug

FDA approved Oxtellar XR from Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) as an adjunctive therapy for epilepsy in adults and children 6-17 years old. The company plans to...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >